NKR 2

Drug Profile

NKR 2

Alternative Names: CAR NKG2D; CAR-T NKR-2; CM-CS-1; NKR 2 T-cell; NKR-2; NKR-2 T-cell immunotherapy; NKR-T cells

Latest Information Update: 08 Jan 2017

Price : $50

At a glance

  • Originator Dartmouth College
  • Developer Celyad; Dana-Farber Cancer Institute
  • Class Antineoplastics; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Angiogenesis inhibitors; Cytotoxic T lymphocyte stimulants; Immunostimulants; NK cell lectin-like receptor subfamily K modulators; Regulatory T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Haematological malignancies; Solid tumours

Most Recent Events

  • 05 Jan 2017 Phase-I/II clinical trials in Solid tumours in Belgium (IV)
  • 24 Nov 2016 Federal agency for Medicines and Health products approves IND application to initiate phase Ib/IIa trial for NKR-2 in Solid tumours and haematological tumours
  • 18 Nov 2016 Efficacy and adverse events data from the phase I portion of a phase I/II trial in Haematological malignancies released by Celyad
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top